In VitroActivity of Fosfomycin and Nitrofurantoin Against ContemporaryEnterobacteralesPathogens Isolated from Indian Tertiary Care Hospitals

Background:In India, multidrug resistance in community and hospital associated Gram-negative pathogens has increased sharply over the past few years. In the absence of novel oral multidrug resistant-pathogen active therapies, the therapeutic situation with regard to community infections is even more challenging. Hence, the focus is now shifting toward potentially expanding the utility of older antibiotics such as fosfomycin and nitrofurantoin beyond their approved pathogen coverage. The current study was undertaken to assess the activity of fosfomycin and nitrofurantoin againstEnterobacteralespathogens through minimum inhibitory concentration (MIC) determination to facilitate monitoring future shifts in susceptibility to these agents. Materials and Methods:The present study used 1,350Enterobacterales, recently collected from various Indian tertiary care hospitals and preserved at Wockhardt Strain Repository. The MIC(50/90)for fosfomycin and nitrofurantoin and the comparator antibiotics was determined forEscherichia coli(N = 470),Klebsiella pneumoniae(N = 429),Enterobacterspp., (N = 144),Proteusspp. (N = 262), andCitrobacterspp. (N = 45), using Clinical and Laboratory Standards Institute recommended agar dilution method. Results:ApplyingE. colibreakpoints, the susceptibility rates of fosfomycin forE. coli,K. pneumoniae,Enterobacterspp.,Proteusspp., andCitrobacterspp., were 95.5%, 53.2%, 71.5%, 76.7%, and 91.1%, respectively. Applying respective breakpoints, the susceptibility rates of comparator drugs, including meropenem, were lower than fosfomycin. Susceptibility of nitrofurantoin forE. coliandCitrobacterisolate was 83%, while limited coverage (<13.2% susceptibility) was observed for other genera. Conclusion:Amidst widespread resistance,a > 70% fosfomycin susceptibility observed for clinical isolates, including strains expressing carbapenemases, is encouraging and supports conducting additional susceptibility and pharmacokinetic/pharmacodynamic studies to explore its potential for expanded therapeutic use. Nitrofurantoin activity spectrum was restricted toE. coliandCitrobacterspp. and, therefore, offers a relatively limited therapeutic scope.

Automated summary

In India, there has been a significant increase in multidrug resistance among Gram-negative pathogens in both community and hospital settings. This study evaluated the activity of fosfomycin and nitrofurantoin against Enterobacterales pathogens, with fosfomycin showing over 70% susceptibility rates, especially among strains expressing carbapenemases. Nitrofurantoin demonstrated limited coverage, mainly effective against E. coli and Citrobacter isolates.